Alkermes PLC, a prominent health care biotechnology company headquartered in Dublin 4, Ireland, has been making significant strides in the development of treatments for central nervous system disorders, including addiction, schizophrenia, depression, and diabetes. As of August 20, 2026, the company’s stock closed at $48.33 on the Nasdaq, where it is publicly traded. This performance is part of a broader financial context, with the stock reaching a 52-week high of $55.67 on July 6, 2026, and a 52-week low of $25.17 on September 7, 2025.
With a market capitalization of approximately $8.11 billion, Alkermes PLC continues to be a significant player in the biotechnology sector. The company’s focus on innovative treatments for complex neurological and metabolic disorders underscores its commitment to addressing some of the most challenging health issues of our time. Despite a high price-to-earnings ratio of 125.09, reflecting investor confidence in its future growth potential, Alkermes PLC remains dedicated to advancing its research and development efforts.
Founded in 1991, Alkermes PLC has a long history of pioneering work in the biotechnology industry. Its strategic focus on central nervous system disorders positions it uniquely within the health care sector, leveraging cutting-edge science to develop therapies that can significantly improve patient outcomes. The company’s efforts are not only aimed at treating existing conditions but also at exploring new therapeutic avenues that could transform the landscape of health care.
For those interested in learning more about Alkermes PLC’s ongoing projects and future directions, detailed information is available on their official website, www.alkermes.com . As the company continues to navigate the complexities of biotechnological innovation, it remains a key entity in the global health care industry, driven by a mission to deliver transformative treatments to patients worldwide.
